文献速递肝病

口服万古霉素、熊去氧胆酸或不治疗用于儿童原发性硬化性胆管炎:一项匹配分析

Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis.
PubMed 文献 · Hepatology · 2021-01-01

该回顾性研究基于儿童原发性硬化性胆管炎联盟数据,将264例接受口服万古霉素、熊去氧胆酸或观察的患儿按倾向评分1:1:1匹配(每组88例)。治疗1年后,各组在γ-谷氨酰转移酶正常化、肝纤维化分期变化及5年肝移植登记概率上均无显著差异;轻度表型及轻微肝纤维化与良好结局相关。

要点

  • 口服万古霉素、熊去氧胆酸与观察组在1年结局指标上均无显著差异。
  • 5年肝移植登记概率三组分别为21%、10%和12%(P无显著差异)。
  • 轻度表型及轻微肝纤维化与良好结局相关,未治疗患儿生化自发正常化常见。

核心结论

  • 口服万古霉素与熊去氧胆酸相比观察策略均未显示结局改善,患者进展至终末期肝病的速率相似。

研究设计与样本

  • 回顾性分析儿童原发性硬化性胆管炎联盟数据,264例患儿按倾向评分1:1:1匹配为口服万古霉素、熊去氧胆酸或观察组,每组88例。

主要发现

  • 口服万古霉素组、熊去氧胆酸组和未治疗组的γ-谷氨酰转移酶正常化比例分别为53%、49%和52%(P无显著差异)。
  • 三组肝纤维化分期改善比例分别为20%、13%和18%,恶化比例分别为11%、29%和18%(P无显著差异)。
  • 三组5年肝移植登记概率分别为21%、10%和12%(P无显著差异)。
  • 良好结局与轻度原发性硬化性胆管炎表型及轻微肝纤维化相关。

临床怎么用

  • 原文结论指出需要安慰剂对照治疗试验以确定儿童原发性硬化性胆管炎的有效治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Many children with primary sclerosing cholangitis (PSC) receive oral vancomycin therapy (OVT) or ursodeoxycholic acid (UDCA). There is a paucity of data on whether these medications improve outcomes. APPROACH AND RESULTS: We analyzed retrospective data from the Pediatric PSC Consortium. Children treated with OVT were matched 1:1:1 to those treated with UDCA or managed with observation (no treatment) based on the closest propensity score, ensuring similar baseline characteristics. Two hundred sixty-four patients (88 each with OVT, UDCA, or observation) had matching propensity scores and were similar in demographics, phenotype, immunosuppression, baseline biochemistry, and hepatic fibrosis. After 1 year in an intention-to-treat analysis, all outcome metrics were similar regardless of treatment group. In OVT, UDCA, and untreated groups, respectively: Gamma-glutamyltransferase normalized in 53%, 49%, and 52% (P = not significant [NS]), liver fibrosis stage was improved in 20%, 13%, and 18% and worsened in 11%, 29%, and 18% (P = NS), and the 5-year probability of liver transplant listing was 21%, 10%, and 12% (P = NS). Favorable outcome was associated with having a mild phenotype of PSC and minimal hepatic fibrosis. CONCLUSIONS: We presented the largest-ever description of outcomes on OVT in PSC and compared them to carefully matched patients on UDCA or no therapy. Neither OVT nor UDCA showed improvement in outcomes compared to a strategy of observation. Patients progressed to end-stage liver disease at similar rates. Spontaneous normalization of biochemistry is common in children receiving no therapy, particularly in the majority of children with a mild phenotype and an early stage of disease. Placebo-controlled treatment trials are needed to identify effective treatments for pediatric PSC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Deneau MR, Mack C, Mogul D, et al. Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis. Hepatology. 2021. PMID: 32946600. doi:10.1002/hep.31560

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。